This Breakthrough Therapy designation is a major derisking event for AP-SA02, providing expedited FDA review and enhanced regulatory engagement. The strong Phase 2 efficacy data (100% vs 75% clinical response) supports a superiority claim in Phase 3. Monitor for Phase 3 initiation in H2 2026 and any partnership or financing announcements given the company's pre-revenue status.
Price Chart
Executive Summary
Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous phage therapy for complicated Staphylococcus aureus bacteremia (including MRSA). The designation is supported by Phase 1b/2a data showing 100% of AP-SA02 patients maintained clinical response at 28 days vs. 75% for placebo, and provides expedited FDA review, cross-disciplinary collaboration, and senior management engagement. This is a significant regulatory milestone that de-risks the Phase 3 program and enhances the asset's value, though the company remains pre-revenue with no financial data in this filing.
Key Facts
- FDA granted Breakthrough Therapy designation to AP-SA02 for adjunct treatment of complicated S. aureus bacteremia (MSSA and MRSA)
- Phase 1b/2a diSArm study: 100% of AP-SA02 patients maintained clinical response at 28 days vs. 75% for placebo
- AP-SA02 now holds Breakthrough Therapy, Fast Track, and QIDP designations
- Phase 3 superiority study anticipated to initiate in second half of 2026
- Development partially supported by a $28.7 million Department of War award
Financial Impact
No financial data in filing; Phase 3 costs partially funded by $28.7M DoW award; Breakthrough Therapy designation may accelerate path to market and reduce development risk
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 results
- Company is pre-revenue and will require additional capital to complete Phase 3 and commercialization
- Bacteriophage therapy is a novel modality with regulatory and manufacturing uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-107253 |
| Document: tm2625289d1_ex99-1.htm | 0001104659-26-107253 |
| Document: 0001104659-26-107253-index-headers.html | 0001104659-26-107253 |
| Document: 0001104659-26-107253-index.html | 0001104659-26-107253 |
| Document: 0001104659-26-107253.txt | 0001104659-26-107253 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $5.55 $4.26 | ▼ −23.24% | ▼ −23.35% | $3.52 (−36.58%) |
Jul 20, 2026 10w ago | 8-K | $5.06 $4.66 | ▼ −7.91% | ▼ −7.48% | $3.52 (−30.43%) |
May 13, 2026 20w ago | 8-K | $8.20 $8.23 | ▼ −0.37% | ▼ −1.08% | $3.52 (+57.07%) |
Apr 27, 2026 22w ago | 8-K | $11.00 $9.85 | ▼ −10.45% | ▼ −10.85% | $3.52 (−68.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access